These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 33800965)

  • 1. Categorization of Marketed Artificial Tear Formulations Based on Their Ingredients: A Rational Approach for Their Use.
    Kathuria A; Shamloo K; Jhanji V; Sharma A
    J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33800965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Critical Appraisal of the Physicochemical Properties and Biological Effects of Artificial Tear Ingredients and Formulations.
    Weng J; Fink MK; Sharma A
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Artificial Tears: Biological Role of Their Ingredients in the Management of Dry Eye Disease.
    Labetoulle M; Benitez-Del-Castillo JM; Barabino S; Herrero Vanrell R; Daull P; Garrigue JS; Rolando M
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative costs of various preserved artificial tear solutions for the treatment of dry eye conditions.
    Enzenauer RW; Kao A; Williams T; Lambert RW
    Eye Contact Lens; 2003 Oct; 29(4):238-40. PubMed ID: 14555900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can the optimum artificial tear treatment for dry eye disease be predicted from presenting signs and symptoms?
    Essa L; Laughton D; Wolffsohn JS
    Cont Lens Anterior Eye; 2018 Feb; 41(1):60-68. PubMed ID: 28811095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of using preservative-free artificial tears versus preserved lubricants for the treatment of dry eyes: a systematic review.
    Ribeiro MVMR; Barbosa FT; Ribeiro LEF; Sousa-Rodrigues CF; Ribeiro EAN
    Arq Bras Oftalmol; 2019 Sep; 82(5):436-445. PubMed ID: 31508669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antioxidant and inflammatory cytokine in tears of patients with dry eye syndrome treated with preservative-free versus preserved eye drops.
    Jee D; Park SH; Kim MS; Kim EC
    Invest Ophthalmol Vis Sci; 2014 Jul; 55(8):5081-9. PubMed ID: 24994869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contrast sensitivity and tear layer aberrometry in dry eye patients.
    Ridder WH; LaMotte J; Hall JQ; Sinn R; Nguyen AL; Abufarie L
    Optom Vis Sci; 2009 Sep; 86(9):E1059-68. PubMed ID: 19648840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of artificial tears on visual performance in subjects with dry eye.
    Ridder WH; Tomlinson A; Paugh J
    Optom Vis Sci; 2005 Sep; 82(9):835-42. PubMed ID: 16189494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety, and acceptability of a lipid-based artificial tear formulation: a randomized, controlled, multicenter clinical trial.
    Simmons PA; Carlisle-Wilcox C; Chen R; Liu H; Vehige JG
    Clin Ther; 2015 Apr; 37(4):858-68. PubMed ID: 25659956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical performance of a mid-viscosity artificial tear for dry eye treatment.
    Simmons PA; Vehige JG
    Cornea; 2007 Apr; 26(3):294-302. PubMed ID: 17413956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stability of fortified cefazolin ophthalmic solutions prepared in artificial tears containing surfactant-based versus oxidant-based preservatives.
    Rojanarata T; Tankul J; Woranaipinich C; Potawanich P; Plianwong S; Sakulma S; Saehuan C
    J Ocul Pharmacol Ther; 2010 Oct; 26(5):485-90. PubMed ID: 20879806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evaluation of tear film breakup time extension and ocular protection index scores among three marketed lubricant eye drops.
    Ousler GW; Michaelson C; Christensen MT
    Cornea; 2007 Sep; 26(8):949-52. PubMed ID: 17721294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of novel lipid-based eye drops with aqueous eye drops for dry eye: a multicenter, randomized controlled trial.
    Simmons PA; Carlisle-Wilcox C; Vehige JG
    Clin Ophthalmol; 2015; 9():657-64. PubMed ID: 25931806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-life results of switching from preserved to preservative-free artificial tears containing hyaluronate in patients with dry eye disease.
    Nasser L; Rozycka M; Gomez Rendon G; Navas A
    Clin Ophthalmol; 2018; 12():1519-1525. PubMed ID: 30197497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of preservatives in artificial tear solutions on tear film evaporation.
    Tomlinson A; Trees GR
    Ophthalmic Physiol Opt; 1991 Jan; 11(1):48-52. PubMed ID: 2034455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Punctal occlusion for dry eye syndrome.
    Ervin AM; Law A; Pucker AD
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD006775. PubMed ID: 28649802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of two preservative-free tear substitutes in the management of severe dry eye.
    Laflamme MY; Swieca R
    Can J Ophthalmol; 1988 Jun; 23(4):174-6. PubMed ID: 3395921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of changing from preserved prostaglandins to preservative-free tafluprost in patients with glaucoma on tear film thickness.
    Hommer A; Schmidl D; Kromus M; Bata AM; Fondi K; Werkmeister RM; Baar C; Schmetterer L; Garhöfer G
    Eur J Ophthalmol; 2018 Jul; 28(4):385-392. PubMed ID: 29592773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-clinical investigation of the efficacy of an artificial tear solution containing hydroxypropyl-guar as a gelling agent.
    Ubels JL; Clousing DP; Van Haitsma TA; Hong BS; Stauffer P; Asgharian B; Meadows D
    Curr Eye Res; 2004 Jun; 28(6):437-44. PubMed ID: 15512952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.